Reviewing Getinge (GNGBY) & Its Competitors

Getinge (OTCMKTS:GNGBY – Get Free Report) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its rivals? We will compare Getinge to related businesses based on the strength of its dividends, earnings, profitability, valuation, analyst recommendations, risk and institutional ownership.

Dividends

Getinge pays an annual dividend of $0.29 per share and has a dividend yield of 1.0%. Getinge pays out 26.4% of its earnings in the form of a dividend. As a group, “Healthcare Providers & Services” companies pay a dividend yield of 1.4% and pay out 25.8% of their earnings in the form of a dividend. Getinge lags its rivals as a dividend stock, given its lower dividend yield and higher payout ratio.

Valuation & Earnings

This table compares Getinge and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Getinge $3.57 billion $230.87 million 25.37
Getinge Competitors $19.23 billion $301.67 million -1.65

Getinge’s rivals have higher revenue and earnings than Getinge. Getinge is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Getinge and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Getinge 8.20% 11.55% 6.15%
Getinge Competitors -7.87% -135.89% -1.58%

Insider and Institutional Ownership

56.7% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 15.0% of shares of all “Healthcare Providers & Services” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Getinge has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Getinge’s rivals have a beta of 0.98, indicating that their average share price is 2% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Getinge and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Getinge 0 4 0 0 2.00
Getinge Competitors 1880 7755 13395 833 2.55

As a group, “Healthcare Providers & Services” companies have a potential upside of 12.77%. Given Getinge’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Getinge has less favorable growth aspects than its rivals.

Summary

Getinge rivals beat Getinge on 11 of the 15 factors compared.

About Getinge

(Get Free Report)

Getinge is a Swedish medical technology company that develops products and services for hospitals and life science organizations. Its offerings support patient care, surgical procedures, infection prevention and the production of medicines and other biological products. The company’s portfolio includes equipment and solutions for intensive care, cardiovascular procedures and operating rooms, as well as sterilization and cleaning systems. Its life science business provides solutions used in areas such as pharmaceutical and biotechnology manufacturing.

Receive News & Ratings for Getinge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Getinge and related companies with MarketBeat.com's FREE daily email newsletter.